Last reviewed · How we verify

NCT04419883

A New Flexible Extended-Length Pharyngeal Airway for Deep Sedation

Completed Last updated 9 June 2020
What this trial tests

trial testing McMurray Enhanced Airway in Upper Airway Obstruction in 86 participants. Completed in 5 May 2020.

Timeline
5 March 2019
Primary endpoint
5 March 2020
5 May 2020

Quick facts

Lead sponsorMcMurray Medical Group, LLC
StatusCompleted
Study typeOBSERVATIONAL
Enrollment86
Start date5 March 2019
Primary completion5 March 2020
Estimated completion5 May 2020
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

McMurray Medical Group, LLC

Who can join

18 and older, any sex, with Upper Airway Obstruction. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this prospective pilot provider adoption study was to evaluate user experience a new airway device in adult patients with airway obstruction under deep sedation. Fifteen hospital systems served as testing sites. Fifty-four anaesthetist providers reported their experience with the airway device in 84 cases across two phases of surveying.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of McMurray Enhanced Airway

Trials testing the same drug.

Other recruiting trials for Upper Airway Obstruction

Currently open trials in the same condition.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04419883.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing